Allergan Aesthetics, an AbbVie company
Botox Cosmetic
A prescription botulinum toxin type A injection that temporarily reduces selected expression lines by weakening targeted muscle activity.
Botulinum toxin type A neuromodulatorReviewed 7/30/2026Source recorded
At a glance
| Primary purpose | Temporary improvement of specified dynamic facial and neck lines in adults; approved US cosmetic areas are product-label specific. |
|---|---|
| Mechanism | Binds to motor nerve terminals and inhibits acetylcholine release by cleaving SNAP-25, producing temporary chemodenervation of injected muscles. |
| When results appear | An effect can begin within 1 to 2 days and commonly strengthens during the first week. |
| Typical sessions | One treatment visit; repeat treatment is considered after the effect wanes and should follow the product label. |
| Downtime | No required recovery period is specified in the label, although injection-site effects can occur. |
| Longevity | The FDA label describes approximately 3 to 4 months for glabellar-line effect; individual areas and patients vary. |
| Reversibility | Not immediately reversible; the effect usually diminishes as neuromuscular function recovers. |
| Documented risks | Unwanted weakness such as eyelid or brow ptosis, asymmetry, headache, hypersensitivity, and rare distant spread of toxin effect with swallowing or breathing difficulty. Contraindicated with hypersensitivity to a botulinum toxin preparation or infection at the injection site. |
| Most common disappointment | Static etched lines or volume loss can remain even when muscle movement is reduced. |
| Common marketing misconception | Botox is not a dermal filler and its potency units cannot be converted directly to another botulinum toxin product. |
| What varies by provider | Muscle assessment, injection sites, dose, depth, symmetry planning, and management of adjacent-muscle spread. |
| When this treatment may not be appropriate | Do not use with product hypersensitivity or infection at the proposed injection site; additional warnings and patient-specific exclusions require prescriber review. |
| United States regulatory status | FDA-approved prescription biologic for temporary improvement of moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands in adults under the current US label. |
| Canadian regulatory status | Health Canada Drug Product Database lists Botox Cosmetic DIN 02531445 as approved; Canadian indications and dosing must follow the current Canadian product monograph. |
| Evidence status | High for product identity, mechanism, labelled indications, contraindications, and labelled duration; outcomes remain dose-, area-, and patient-dependent. |
Sources
- BOTOX Cosmetic prescribing informationregulator
- BOTOX Cosmetic US Prescribing InformationFDA prescribing information · regulatory-primary · supports 23 profile fields
- FDA approval letter for BOTOX CosmeticFDA approval record · regulatory-primary · supports 2 profile fields
- Health Canada Drug Product Database: Botox Cosmetic DIN 02531445Health Canada DPD · regulatory-primary
Related comparisons
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.